We are conducting a clinical trial to determine whether a short-term treatment with a medication reduces the risk of death and lung complications related to COVID-19.
• Involves the daily intake of study medication or placebo;
• Participation of 30 days;
• Only 2 follow-up calls or video-visits are required during follow-up;
• Be 40 and over;
• COVID-19 positive diagnosis;
• Not hospitalized;
• Forbidden to pregnant women, who are breastfeeding or who do not use contraception.
A new coronavirus is responsible for causing coronavirus
disease (COVID-19). While the majority of cases are mild,
a certain number of people progress to severe disease with complications.
Adults who suffer major COVID-19 complications appear to present a major inflammatory storm (overreaction of immune system). Therefore, we hypothesize that targeting the inflammatory response (originating from the inflammasome) may reduce COVID-19-related complications in adults at risk or with evidence of an inflammatory storm.
The primary objective of the COLCORONA study is to determine whether short-term treatment with a particular medication reduces the rate of death and lung complications related to COVID-19. COLCORONA will be a randomized, double-blind, placebo-controlled study. Following signature of the informed consent form, 6000 subjects meeting all inclusion and no exclusion criteria will be enrolled.